Cancer UrologyCancer UrologyОнкоурология1726-97761996-1812Publishing House ABV Press124910.17650/1726-9776-2006-2-1-61-68REVIEWОБЗОРRadionuclide therapy in the treatment of patients with prostatic cancer with metastases in the bonesРадионуклидная терапия в лечении больных раком предстательной железы с метастазами в костиKrylovV. V.КрыловВ. В.Russian Federation
1. Модников О.П., Новиков Г.А., Родионов В.В. Современные подходы к лечению множественного метастатического поражения костей // Курс лекций по паллиативной помощи онкологическим больным / Под ред. Г.А Новикова., В.И. Чиссова, О.П. Модникова. – М., 2004. – Т. 1. – С. 493–541.Модников О.П., Новиков Г.А., Родионов В.В. Современные подходы к лечению множественного метастатического поражения костей // Курс лекций по паллиативной помощи онкологическим больным / Под ред. Г.А Новикова., В.И. Чиссова, О.П. Модникова. – М., 2004. – Т. 1. – С. 493–541.2. Enrique O., Zhongyun P., Parma E.P. et al. Efficacy and toxicity of Sm-153-EDTMP in the palliative treatment of painful bone metastases // World J. Nucl. Med. – 2002; 1 (1):21–27.Enrique O., Zhongyun P., Parma E.P. et al. Efficacy and toxicity of Sm-153-EDTMP in the palliative treatment of painful bone metastases // World J. Nucl. Med. – 2002; 1 (1):21–27.3. Исакова М.Е. Проблема боли в онкологии // РМЖ. – 2000. – Т. 8, №17.Исакова М.Е. Проблема боли в онкологии // РМЖ. – 2000. – Т. 8, №17.4. Кондратьева А.П. Новое в лечении костных метастазов // РМЖ. – 1999. – Т.7, №10.Кондратьева А.П. Новое в лечении костных метастазов // РМЖ. – 1999. – Т.7, №10.5. Моисеенко В.М., Блинов Н.Н. Современная тактика лечения больных злокачественными новообразованиями с метастазами в кости. Пособие для врачей. – СПб., 1996.Моисеенко В.М., Блинов Н.Н. Современная тактика лечения больных злокачественными новообразованиями с метастазами в кости. Пособие для врачей. – СПб., 1996.6. Нестеренко В.М., Новиков Г.А., Борисов В.И. Причины развития, типы и клинические проявления костных метастазов // Паллиативная медицина и реабилитация. – 1998. – №6. – С. 38–41.Нестеренко В.М., Новиков Г.А., Борисов В.И. Причины развития, типы и клинические проявления костных метастазов // Паллиативная медицина и реабилитация. – 1998. – №6. – С. 38–41.7. Chakraborty S., Das T., Unni P.R. et al. 177Lu labelled polyaminopshonates as potential agents for bone pain palliation // Nuc. Med. Communications. – 2002; 23: 67—74.Chakraborty S., Das T., Unni P.R. et al. 177Lu labelled polyaminopshonates as potential agents for bone pain palliation // Nuc. Med. Communications. – 2002; 23: 67—74.8. Turner J.H. Treatment of painful skeletal metastases // Alasbimn J. Special Issue: 8-th World Congress of Nuclear Medicine. – 2002; Sept. 17.Turner J.H. Treatment of painful skeletal metastases // Alasbimn J. Special Issue: 8-th World Congress of Nuclear Medicine. – 2002; Sept. 17.9. Корытова Л.И., Сухов В.Ю., Шутко А.Н., Карелин М.И., Хозова Т.В. Применение «Метастрона» в лечении больных с костными метастазами. Пособие для врачей. – СПб., 1997.Корытова Л.И., Сухов В.Ю., Шутко А.Н., Карелин М.И., Хозова Т.В. Применение «Метастрона» в лечении больных с костными метастазами. Пособие для врачей. – СПб., 1997.10. Ли Л.А. Клиника, диагностика и лечение метастазов рака молочной железы. Пособие для врачей. – Л., 1990.Ли Л.А. Клиника, диагностика и лечение метастазов рака молочной железы. Пособие для врачей. – Л., 1990.11. Цыб А.Ф., Дроздовский Б.Я., Крылов В.В., Кодина Г.Е. Паллиативная терапия самарием-оксабифором, 153Sm при метастатических поражениях костей // Медицинская радиология и радиационная безопасность. – 2002. – Т. 48, №4.Цыб А.Ф., Дроздовский Б.Я., Крылов В.В., Кодина Г.Е. Паллиативная терапия самарием-оксабифором, 153Sm при метастатических поражениях костей // Медицинская радиология и радиационная безопасность. – 2002. – Т. 48, №4.12. Cleeland Ch.S., Conin R., Hotfield H.K. et al. Pain and its treatment in outpatrents with metastatic cancer // N. Eng. J. Med. – 1994; 330,592–596.Cleeland Ch.S., Conin R., Hotfield H.K. et al. Pain and its treatment in outpatrents with metastatic cancer // N. Eng. J. Med. – 1994; 330,592–596.13. Boissier S., Ferreras M., Peyruchaud O. et al. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases // Cancer Res. – 2000; 60:2949–2954.Boissier S., Ferreras M., Peyruchaud O. et al. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases // Cancer Res. – 2000; 60:2949–2954.14. Nussbaum S.R., Younger I. et al. Single-dose intravenous therapy with pamidronate for the treatment of hypercalciemia of malignancy: comparison of 30-, 60-, and 90-mg dosages // Am. J. Med. – 1993; 95:297–304.Nussbaum S.R., Younger I. et al. Single-dose intravenous therapy with pamidronate for the treatment of hypercalciemia of malignancy: comparison of 30-, 60-, and 90-mg dosages // Am. J. Med. – 1993; 95:297–304.15. Coleman R.E., Purohit O.P. Osteoclast inhibition for the treatment of bone metastases // Cancer. Treat. Rev. – 1993;19:79–103.Coleman R.E., Purohit O.P. Osteoclast inhibition for the treatment of bone metastases // Cancer. Treat. Rev. – 1993;19:79–103.16. Fettich J., Padhy A., Nair N., Morales R. et al. Comparative clinical efficacy and safety of 32P and 89Sr in the palliative treatment of metastatic Bone Pain: results of an IAEA coordinated research project // World Nucl. Med. – 2003; 2 (3):226–231.Fettich J., Padhy A., Nair N., Morales R. et al. Comparative clinical efficacy and safety of 32P and 89Sr in the palliative treatment of metastatic Bone Pain: results of an IAEA coordinated research project // World Nucl. Med. – 2003; 2 (3):226–231.17. Hoegler D. Radiotherapy for palliation of symptoms in incurable cancer // Curr. Probl. Cancer. – 1997; 21 (3), 129–183.Hoegler D. Radiotherapy for palliation of symptoms in incurable cancer // Curr. Probl. Cancer. – 1997; 21 (3), 129–183.18. Hoefnagel C.A., Clarke S.E.M., Fischer M. et al. Radionuclide therapy practice and facilities in Europe // Eur. J. Nucl. Med. – 1999; 26: 277–282.Hoefnagel C.A., Clarke S.E.M., Fischer M. et al. Radionuclide therapy practice and facilities in Europe // Eur. J. Nucl. Med. – 1999; 26: 277–282.19. Anderson P.M., Wiseman G.A., Dispenzieri A. et al. High-dose samarium-153 ethylenediaminetetramethylene phosphonate: low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases // J. Clin. Oncol. – 2002; 20:1, 189–196.Anderson P.M., Wiseman G.A., Dispenzieri A. et al. High-dose samarium-153 ethylenediaminetetramethylene phosphonate: low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases // J. Clin. Oncol. – 2002; 20:1, 189–196.20. Bishayee A., Rao D.V., Srivastava C. et al. Marrow-sparing effects of 117m Sn (4+) diethylenetriaminepentaacetic acid for radionuclide therapy of bone cancer // J. Nucl. Med. – 2000; 41:2043–2050.Bishayee A., Rao D.V., Srivastava C. et al. Marrow-sparing effects of 117m Sn (4+) diethylenetriaminepentaacetic acid for radionuclide therapy of bone cancer // J. Nucl. Med. – 2000; 41:2043–2050.21. Goddu S.M., Bishayee A., Bouchet L.G. et al. Marrow toxicity of 33P versus 32P-Orthophosphate: implications for therapy of bone pain and bone metastases // J. Nucl. Med. – 2000; 41:5, 941–951.Goddu S.M., Bishayee A., Bouchet L.G. et al. Marrow toxicity of 33P versus 32P-Orthophosphate: implications for therapy of bone pain and bone metastases // J. Nucl. Med. – 2000; 41:5, 941–951.22. Ketring A. 153Sm-EDTMP and 186ReHEDP as bone therapeutic radiopharmaceuticals // Nucl. Med. Biol. – 1987; 14:223–232.Ketring A. 153Sm-EDTMP and 186ReHEDP as bone therapeutic radiopharmaceuticals // Nucl. Med. Biol. – 1987; 14:223–232.23. Krishnamurthy G.T., Krishnamurthy S. Radionuclides for metastatic bone pain palliation: a need for rational re-evaluation in the new millennium // J. Nucl Med. – 2000; 41 (4):688–691.Krishnamurthy G.T., Krishnamurthy S. Radionuclides for metastatic bone pain palliation: a need for rational re-evaluation in the new millennium // J. Nucl Med. – 2000; 41 (4):688–691.24. Liepe K., Hliscs R., Kropp J. et al. Rhenium-188 HEDP in the palliative treatment of bone metastases // Cancer Biotherapy & Radiopharmaceuticals. – 2000; 15(3):261–265.Liepe K., Hliscs R., Kropp J. et al. Rhenium-188 HEDP in the palliative treatment of bone metastases // Cancer Biotherapy & Radiopharmaceuticals. – 2000; 15(3):261–265.25. Maxon H., Schroder L., Washurn L. Rhenium-188 HEDP for treatment of osseous metastases // J. Nucl. Med. – 1998; 39:659–663.Maxon H., Schroder L., Washurn L. Rhenium-188 HEDP for treatment of osseous metastases // J. Nucl. Med. – 1998; 39:659–663.26. Mc Ewan A.J. et al. A retrospective analysis of the cost effectiveness of treatment with Metastron in patients with prostate cancer metastatic to bone // Eur. Urol. – 1994; 26 (1):26–31.Mc Ewan A.J. et al. A retrospective analysis of the cost effectiveness of treatment with Metastron in patients with prostate cancer metastatic to bone // Eur. Urol. – 1994; 26 (1):26–31.27. Schmeler H., Bastin K. Strontium-89 for symptomatic metastatic prostate cancer in bone: Recommendations for hospice patients // The Hospice J. – 1996; 11:2–10.Schmeler H., Bastin K. Strontium-89 for symptomatic metastatic prostate cancer in bone: Recommendations for hospice patients // The Hospice J. – 1996; 11:2–10.28. Holmes R. [153Sm] EDTMP: A Potential Therapy for Bone Cancer Pain // Seminars in Nucl. Med. – 1992. – V. XXII, №1. – P. 41–45.Holmes R. [153Sm] EDTMP: A Potential Therapy for Bone Cancer Pain // Seminars in Nucl. Med. – 1992. – V. XXII, №1. – P. 41–45.29. Oh S.J., Won K.S., Moon D.H. et al. Preparation and biological evaluation of 188Re-ethylenediamine-N,N,N1,N1- tetrakis (methylenephosphonic acid) as a potential agent for bone pain palliation // Nucl. Med. Communications. – 2002; 23:75–81.Oh S.J., Won K.S., Moon D.H. et al. Preparation and biological evaluation of 188Re-ethylenediamine-N,N,N1,N1- tetrakis (methylenephosphonic acid) as a potential agent for bone pain palliation // Nucl. Med. Communications. – 2002; 23:75–81.30. Nair N. Relative efficacy of 32P and 89Sr in palliation in skeletal metastases // J. Nucl. Med. – 1999; 40:256–-261.Nair N. Relative efficacy of 32P and 89Sr in palliation in skeletal metastases // J. Nucl. Med. – 1999; 40:256–-261.31. Palmedo H., Bender H., DierkeDzierzon C. et al. Pain palliation with rhenium-186-HEDP in breast cancer patients with disseminated bone metastases // Clin. Nucl. Med. – 1999; 24:643–648.Palmedo H., Bender H., DierkeDzierzon C. et al. Pain palliation with rhenium-186-HEDP in breast cancer patients with disseminated bone metastases // Clin. Nucl. Med. – 1999; 24:643–648.32. Robinson RG., Spicer J.A., Preston D.F. et al. Treatment of metastatic bone pain with strontium-89 // Nucl. Med. Biol. – 1987; 14:219–222.Robinson RG., Spicer J.A., Preston D.F. et al. Treatment of metastatic bone pain with strontium-89 // Nucl. Med. Biol. – 1987; 14:219–222.33. Sevilla A., Salgado L., Fonseca A.T., Vieira M.R. Is early Sr-89-Therapy useful in prostate cancer patient with bone metastasis? // World J. Nucl. Med. – 2002; 1 (2): 276.Sevilla A., Salgado L., Fonseca A.T., Vieira M.R. Is early Sr-89-Therapy useful in prostate cancer patient with bone metastasis? // World J. Nucl. Med. – 2002; 1 (2): 276.34. Resche I., Chatal J.-F., Pecking A. et al. A dose-controlled study of 153SmEthylenediaminetetramethylenephosphona te (EDTMP) in the treatment of patients with painful bone metastases // Eur. J. Cancer. – 1997; 33(10):1583–1591.Resche I., Chatal J.-F., Pecking A. et al. A dose-controlled study of 153SmEthylenediaminetetramethylenephosphona te (EDTMP) in the treatment of patients with painful bone metastases // Eur. J. Cancer. – 1997; 33(10):1583–1591.35. Bayouth J.E., Macey D.J., Kasi L.P., Fossella F.V. Dosimetry and Toxicity of Samarium-153-EDTMP Administried for Bone Pain Due to skeletal metastases // J. Nucl. Med. – 1994; 35: 63–69.Bayouth J.E., Macey D.J., Kasi L.P., Fossella F.V. Dosimetry and Toxicity of Samarium-153-EDTMP Administried for Bone Pain Due to skeletal metastases // J. Nucl. Med. – 1994; 35: 63–69.36. Eary J.F., Collins C., Stabin M. et al. Samarium- 153-EDTMP biodistribution and dosimetry estimation // J. Nucl. Med. – 1993; 34:1031–1036.Eary J.F., Collins C., Stabin M. et al. Samarium- 153-EDTMP biodistribution and dosimetry estimation // J. Nucl. Med. – 1993; 34:1031–1036.37. Farhangi M., Holmes R.A., Volkert W.A. et al. Samarium-153-EDTMP: pharmacokinetic, toxicity and pain response using an escalating dose schedule in treatment of metastatic bone cancer // J. Nucl. Med. – 1992; 33;1451–1458.Farhangi M., Holmes R.A., Volkert W.A. et al. Samarium-153-EDTMP: pharmacokinetic, toxicity and pain response using an escalating dose schedule in treatment of metastatic bone cancer // J. Nucl. Med. – 1992; 33;1451–1458.38. Collins C., Eary J.F., Donaldson G. et al. Samarium-153-EDTMP in bone metastases of hormone refractory prostate carcinoma: a phase I/II trial // J. Nucl. Med. – 1993;.34;1839–1844.Collins C., Eary J.F., Donaldson G. et al. Samarium-153-EDTMP in bone metastases of hormone refractory prostate carcinoma: a phase I/II trial // J. Nucl. Med. – 1993;.34;1839–1844.39. Sciuto R., Tofani A., Festa A. et al. Short and long-term effects of 186Re-1, 1-hydroxyethylidene diphosphonate in the treatment of painful bone metastases // J. Nucl. Med. – 2000; 41:647–654.Sciuto R., Tofani A., Festa A. et al. Short and long-term effects of 186Re-1, 1-hydroxyethylidene diphosphonate in the treatment of painful bone metastases // J. Nucl. Med. – 2000; 41:647–654.40. Kaplan E. Historical development of P-32 in bony therapy / Spencer R.P. (ed): Therapy in Nuclear Medicine. – Philadelphia, PA, Saunders, 1978. – P. 237–249.Kaplan E. Historical development of P-32 in bony therapy / Spencer R.P. (ed): Therapy in Nuclear Medicine. – Philadelphia, PA, Saunders, 1978. – P. 237–249.41. Johnson D.E., Haynie T.P. Phosphorus- 32 for untreatable pain in carcinoma of prostate. Analysis and androgen primary, parathormone, rebound and combination therapy // J. Urol. – 1977; 9:137–139.Johnson D.E., Haynie T.P. Phosphorus- 32 for untreatable pain in carcinoma of prostate. Analysis and androgen primary, parathormone, rebound and combination therapy // J. Urol. – 1977; 9:137–139.42. Han S. H., de Klerk J.M.N., Tan.S. et al. The Placorhen Stady: a double-blind, placebo controlled, randomized radionuklide study with Re-186-Etidronate in hormono-resistant prostate cancer patients with painful bone metastases // J. Nucl. Med. – 2002. – V. 43., №9. – 1150–1156.Han S. H., de Klerk J.M.N., Tan.S. et al. The Placorhen Stady: a double-blind, placebo controlled, randomized radionuklide study with Re-186-Etidronate in hormono-resistant prostate cancer patients with painful bone metastases // J. Nucl. Med. – 2002. – V. 43., №9. – 1150–1156.43. Limouris G., Shukia S., Manetou A. et al. Rhenium-186-HEDP-palliative treatment in disseminated bone metastases due to prostate cancer // Anticancer Res. – 1997; 17:1699–1704.Limouris G., Shukia S., Manetou A. et al. Rhenium-186-HEDP-palliative treatment in disseminated bone metastases due to prostate cancer // Anticancer Res. – 1997; 17:1699–1704.44. Srivastava S.C., Atkins H.L., Krishnamurthy G.T. et al. Treatment of metastatic bone pain with tin-117m stannic diethylenetriamine pentaacetic acid: a phase I/II clinical study // Clin. Cancer Res. – 1998; 4:61–68.Srivastava S.C., Atkins H.L., Krishnamurthy G.T. et al. Treatment of metastatic bone pain with tin-117m stannic diethylenetriamine pentaacetic acid: a phase I/II clinical study // Clin. Cancer Res. – 1998; 4:61–68.45. Lin W.-Y., Lin C.-P., Yeh S.-J. et al. Rhenium-188 hydroxyethylidene diphosphonate: a new generator-produced radiotherapeutic drug of potential value for the treatment of bone metastases // Eur. J. Nucl. Med. – 1997; 24:590–595.Lin W.-Y., Lin C.-P., Yeh S.-J. et al. Rhenium-188 hydroxyethylidene diphosphonate: a new generator-produced radiotherapeutic drug of potential value for the treatment of bone metastases // Eur. J. Nucl. Med. – 1997; 24:590–595.46. Lewington V.J. Cancer therapy using bone-seeking isotopes // Phys. Med. Biol. – 1996; 41:2027–2042.Lewington V.J. Cancer therapy using bone-seeking isotopes // Phys. Med. Biol. – 1996; 41:2027–2042.47. Palmedo H., Guhlke S., Bender H. et al. Dose escalation study with Re-188 HEDP in prostate cancer patients with osseous metastases // J. Nucl. Med. – 1999; 5:218P.Palmedo H., Guhlke S., Bender H. et al. Dose escalation study with Re-188 HEDP in prostate cancer patients with osseous metastases // J. Nucl. Med. – 1999; 5:218P.48. Mertens W.C., Stitt L., Porter A.T. Strontium-89 therapy and relief of pain in patients with prostatic carcinoma metastatic to bone: A dose response relationship // Am. J. Clin. Oncol. – 1993; 16(3): 238–242.Mertens W.C., Stitt L., Porter A.T. Strontium-89 therapy and relief of pain in patients with prostatic carcinoma metastatic to bone: A dose response relationship // Am. J. Clin. Oncol. – 1993; 16(3): 238–242.49. Silberstein E.B., Buscombe J.R., Mc. Ewans A., Taylor A.T. Society of nuclear medicine procedure guideline for palliative treatment of painful bone metastases // Society of nuclear medicine procedure guidelines manual. – 2003. – P. 145 – 153.Silberstein E.B., Buscombe J.R., Mc. Ewans A., Taylor A.T. Society of nuclear medicine procedure guideline for palliative treatment of painful bone metastases // Society of nuclear medicine procedure guidelines manual. – 2003. – P. 145 – 153.50. Robinson RG. Radionuclides for the alleviation of bone pain in advanced malignancy // Clin. Oncol. – 1986; 5:39–49.Robinson RG. Radionuclides for the alleviation of bone pain in advanced malignancy // Clin. Oncol. – 1986; 5:39–49.51. Serafini A.N., Kuker R.A., Fernandez G. et al. Evaluation of Sm-153 EDTMP as a Tumoricidal Agent in Prostate Cancer // World J. Nucl. Med. – 2002; 1 (2):136.Serafini A.N., Kuker R.A., Fernandez G. et al. Evaluation of Sm-153 EDTMP as a Tumoricidal Agent in Prostate Cancer // World J. Nucl. Med. – 2002; 1 (2):136.52. Sinzinger H., Weiss K., Granegger S., Hajek C. Repeated low-dose vs. single higtdose 153 EDTMP treatment. Advantages and disadvantages // World J. Nucl. Med. – 2002; 1 (2):69.Sinzinger H., Weiss K., Granegger S., Hajek C. Repeated low-dose vs. single higtdose 153 EDTMP treatment. Advantages and disadvantages // World J. Nucl. Med. – 2002; 1 (2):69.53. Ferretti G., Povolato M., Bisssoli S. 89-SrCl and 153-Sm EDTMP radiometabolic treatment of metastatic bone pain (MBP) in prostate cancer (PC): our experience // Alasbimn J. – Special Issue: 8-th World Congress of Nuclear Medicine. – 2002; sept. 17.Ferretti G., Povolato M., Bisssoli S. 89-SrCl and 153-Sm EDTMP radiometabolic treatment of metastatic bone pain (MBP) in prostate cancer (PC): our experience // Alasbimn J. – Special Issue: 8-th World Congress of Nuclear Medicine. – 2002; sept. 17.